Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06791070 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum

Study acronym: RC48&J for EPD
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of this clinical trial is to learn if Disitamab Vedotin combined with Toripalimab works to treat advanced HER2-positive extramammary Paget disease of the scrotum. It will also learn about the safety of this combination. The main questions it aims to answer are: Does this combination reduce tumor volume and delay disease progression? What medical problems do participants have when receving this combination? Participants will: Intravenous using this combination every 3 weeks until disease progression or intolerable adverse reactions occur. Visit the clinic once every 3 weeks for checkups and tests.
Trial Details
NCT Number NCT06791070
Lead Sponsor Fujian Medical University Union Hospital
Collaborators: Zhejiang Tumor Hospital, Fujian Provincial Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Quanzhou First Hospital, First Affiliated Hospital of Wenzhou Medical University
Conditions
(from sponsor)		 Paget Disease, Extramammary, Scrotum Disease
Related terms Paget Disease, Extramammary
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov